University of Iowa Research Foundation

Protein Design Labs, Inc.

Coley Pharmaceutical Gmbh

Pdl Biopharma, Inc.

Checkmate Pharmaceuticals, Inc.

Iowa Immunotherapy Investigators

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Abbott Biotherapeutics Corp.

George J Weiner

Arthur Mertz Krieg

Dennis M Klinman

J Yun Tso

Aliasger Karimjee Salem

Michael B Cohen

Roger Gingrich

Brian K Link

Oskar W Rokhlin

Gunther Hartmann

Paloma H Giangrande

David E Elliott

William Thiel

Aaron Jay Morris

Sean M Geary

Suresh Veeramani

Vijaya B Joshi

Mirac Nedim Ince

Sue Blackwell

David Mauro

Mohammed Milhem

Laura M Rogers

Adam J Dupuy

Caitlin Lemke

Amani Makkouk

Yogita Krishnamachari

Emilian V Racila

Brian Link

Roger Dept Of Internal Medicine Gingrich

Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Compositions and methods for tumor immunotherapy

Disclosed are compositions, kits, and methods for identifying genes that are involved in T-cell trafficking. In particular, the compositions, kits, and methods may be used to identify genes involved in T-cell trafficking and/or infiltration into tumors such as genes that encode immune checkpoint regulators and/or stimulatory agents. The disclosed compositions, kits, and methods utilize the Sleeping Beauty® transposon system in a mouse tumor model to identify genes that are involved in T-cell trafficking and infiltration into tumors. The genes identified in the disclosed methods may provide immunotherapy targets in the tumor microenvironment. The identified genes may be utilized in order to develop therapies that enhance T-cell trafficking and infiltration into tumors and/or T-cell killing of tumors such as in chimeric antigen receptor (CAR) T cell therapies.

Identification of T-cell trafficking genes and uses thereof for increasing infiltration of T-cells into solid tumors

Disclosed herein are compositions including an aptamer bound to a complex, wherein the complex comprises at least two polypeptides. Accordingly, methods of using the aptamers and making the aptamers are also disclosed.

Nucleic acid aptamers

Disclosed are compositions, kits, and methods for treating cancer in a subject in need thereof. The compositions, kits, and methods may be used to treat a tumor in a subject in situ. The compositions, kits, and methods comprise or utilize cytotoxic particles, immune checkpoint inhibitors, and/or T-cell stimulatory agents.

Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy

The invention relates to helminthic parasite preparations and their use for treatment or prevention of GVHD in a subject that has undergone a transplant. The invention also related to helminthic parasite preparations and their use for prevention of GVHD in a subject prior to a transplant.

Parasitic biological agents for treatment and prevention of graft versus host disease

The present invention provides three-component compositions comprising microparticles, a tumor antigen, a first immune adjuvant, and a second immune adjuvant. Also provided are chemo-immunotherapeutic compositions comprising microparticles, a chemotherapeutic agent, and an immune adjuvant.

Biodegradable particulate formulations

The present invention encompasses methods for predicting metastasis in cancer by assessing the structure of the complement protein C1qA. The methods may encompass examining either protein or nucleic acids, and may further include making treatment decisions based on the predictive methods.

Assessing response to anti-CD20 therapy by genotyping C1q components

The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening cancer cells.

Methods for enhancing antibody-induced cell lysis and treating cancer

The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.

Humanized antibodies against CD3

Disclosed is an antibody that binds to a protein found on normal and cancerous prostate cells, but not found on nonprostate cells and a hybridoma that produces the antibody to the prostate-specific protein. Also disclosed are antibodies conjugated to labels or cytotoxic moieties.

Prostate cell surface antigen-specific antibodies

The present invention relates to synergistic combinations of immunostimulatory CpG oligonucleotides and immunopotentiating cytokines. In particular, the invention relates to methods of stimulating an immune response using the synergistic combination of compounds and products related thereto.

Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Bispecific antibody effective to treat B-cell lymphoma and cell line

Growing community of inventors

Iowa City, IA, United States of America

George J Weiner